Biotechnology Value Trading Fund OS LP — SEC Form 4 filings
SEC reporting owner CIK 1660683. 32 Form 4 filings on record with FilingPulse; latest filed 2026-09-18.
Transaction summary — filings shown
Covers all 32 filings on record, filed 2024-01-09 to 2026-09-18. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 6 legs across 2 filings — 2,245,104 shares, $13,955,348 total (shares × price as filed on priced legs).
- Open-market sales (code S, non-derivative): 22 legs across 7 filings — 9,424,254 shares, $378,557,577 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 86.
- Largest priced transaction: sale of 837,914 shares @ $106.50 ($89,237,841) in Kymera Therapeutics, Inc., filed 2026-06-26.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | Director | 6 | 3 legs · 317,167 sh · $13,955,348 | 4 legs · 1,630,658 sh · $173,665,077 | 8 |
| MoonLake Immunotherapeutics (MLTX) | Director | 5 | — | 6 legs · 5,750,000 sh · $162,965,700 | 3 |
| XOMA Royalty Corp (XOMA) | — | 4 | — | 6 legs · 1,043,440 sh · $27,626,507 | 12 |
| Third Harmonic Bio, Inc. (THRD) | — | 1 | — | 3 legs · 1,000,000 sh · $14,300,000 | — |
| ESSA Pharma Inc. (EPIX) | — | 2 | — | 3 legs · 156 sh · $293 | 9 |
| Eledon Pharmaceuticals, Inc. (ELDN) | — | 2 | 3 legs · 1,927,937 sh | — | 6 |
| Olema Pharmaceuticals, Inc. (OLMA) | Director | 5 | — | — | 18 |
| Rain Oncology Inc. (RAIN) | Director | 1 | — | — | 8 |
| 4D Molecular Therapeutics, Inc. (FDMT) | — | 1 | — | — | 6 |
| GLYCOMIMETICS INC (CBIO) | — | 1 | — | — | 6 |
+4 more issuers among the filings shown — every filing appears in the table below.
Form 4 filings — Biotechnology Value Trading Fund OS LP
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-18 | 4 | IMMUNIC, INC. (IMUX) jointly with BVF PARTNERS L P/IL, BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL, LAMPERT MARK N | Grant/award (A): 25,370 (derivative) @ $0 | EDGAR |
| 2026-07-16 | 4 | XOMA Royalty Corp (XOMA) jointly with BVF PARTNERS L P/IL, BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL, LAMPERT MARK N | Code (U): 3,635,758 · Code (U): 2,773,545 · Code (U): 412,000 · Code (U): 772,000 | EDGAR |
| 2026-06-26 | 4 | Kymera Therapeutics, Inc. (KYMR) jointly with BVF PARTNERS L P/IL, BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL, LAMPERT MARK N | Sale (S): 837,914 @ $106.50 · Sale (S): 627,597 @ $106.50 · Sale (S): 113,289 @ $106.50 · Sale (S): 51,858 @ $106.50 | EDGAR |
| 2026-06-25 | 4 | Kymera Therapeutics, Inc. (KYMR) jointly with BVF PARTNERS L P/IL, BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL, LAMPERT MARK N | Grant/award (A): 6,068 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Olema Pharmaceuticals, Inc. (OLMA) jointly with BVF PARTNERS L P/IL, BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL, LAMPERT MARK N | Grant/award (A): 29,500 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | MoonLake Immunotherapeutics (MLTX) jointly with BVF PARTNERS L P/IL, BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL, LAMPERT MARK N | Grant/award (A): 22,195 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | XOMA Royalty Corp (XOMA) jointly with BVF PARTNERS L P/IL, BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL, LAMPERT MARK N | Conversion (C): 2,313,000 @ $4.03 · Conversion (C): 1,506,000 @ $4.03 · Conversion (C): 412,000 @ $4.03 · Conversion (C): 772,000 @ $4.03 · Conversion (C): 2,313 (derivative) @ $0 · Conversion (C): 1,506 (derivative) @ $0 · +2 more | EDGAR |
| 2026-04-02 | 4 | MoonLake Immunotherapeutics (MLTX) jointly with BVF PARTNERS L P/IL, BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL, LAMPERT MARK N | Sale (S): 1,932,354 @ $16.79 · Sale (S): 1,569,116 @ $16.79 · Sale (S): 248,530 @ $16.79 | EDGAR |
| 2026-01-30 | 4 | Repare Therapeutics Inc. (RPTX) jointly with BVF PARTNERS L P/IL, BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL, LAMPERT MARK N | Code (U): 5,309,432 · Code (U): 4,308,573 · Code (U): 548,938 | EDGAR |
| 2025-10-14 | 4 | ESSA Pharma Inc. (EPIX) jointly with BVF PARTNERS L P/IL, BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL, LAMPERT MARK N | Code (U): 6,194,145 · Code (U): 4,726,743 · Code (U): 560,797 | EDGAR |
| 2025-08-07 | 4 | ESSA Pharma Inc. (EPIX) jointly with BVF PARTNERS L P/IL, BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL, LAMPERT MARK N | Option exercise/expiry (X): 1,481,634 @ $0.00 · Option exercise/expiry (X): 1,235,030 @ $0.00 · Option exercise/expiry (X): 203,336 @ $0.00 · Sale (S): 79 @ $1.88 · Sale (S): 66 @ $1.88 · Sale (S): 11 @ $1.88 · +3 more | EDGAR |
| 2025-07-01 | 4 | Kymera Therapeutics, Inc. (KYMR) jointly with BVF PARTNERS L P/IL, BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL, LAMPERT MARK N | Purchase (P): 142,604 @ $44 · Purchase (P): 115,783 @ $44 · Purchase (P): 58,780 @ $44 · Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2025-06-17 | 4 | GLYCOMIMETICS INC (CBIO) jointly with BVF PARTNERS L P/IL, BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL, LAMPERT MARK N | Other (J): 657,308 · Other (J): 556,617 · Other (J): 56,079 · Other (J): 304,098 (derivative) · Other (J): 257,515 (derivative) · Other (J): 25,944 (derivative) | EDGAR |
| 2025-06-13 | 4 | Olema Pharmaceuticals, Inc. (OLMA) jointly with BVF PARTNERS L P/IL, BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL, LAMPERT MARK N | Grant/award (A): 24,150 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | MoonLake Immunotherapeutics (MLTX) jointly with BVF PARTNERS L P/IL, BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL, LAMPERT MARK N | Grant/award (A): 6,682 (derivative) @ $0 | EDGAR |
| 2025-05-20 | 4 | XOMA Royalty Corp (XOMA) jointly with BVF PARTNERS L P/IL, BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL, LAMPERT MARK N | Sale (S): 127,407 @ $27.10 · Sale (S): 265,316 @ $27.10 | EDGAR |
| 2025-05-19 | 4 | Allakos Inc. (ALLK) jointly with BVF PARTNERS L P/IL, BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL, LAMPERT MARK N | Disposition to issuer (D): 8,679,726 · Disposition to issuer (D): 6,777,935 · Disposition to issuer (D): 855,211 | EDGAR |
| 2025-01-28 | 4 | XOMA Royalty Corp (XOMA) jointly with BVF PARTNERS L P/IL, BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL, LAMPERT MARK N | Sale (S): 339,679 @ $26.10 · Sale (S): 85,776 @ $26.10 · Sale (S): 75,287 @ $26.10 · Sale (S): 149,975 @ $26.10 | EDGAR |
| 2025-01-14 | 4 | Olema Pharmaceuticals, Inc. (OLMA) jointly with BVF PARTNERS L P/IL, BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL, LAMPERT MARK N | Disposition to issuer (D): 235,450 · Disposition to issuer (D): 161,810 · Disposition to issuer (D): 22,740 · Grant/award (A): 235,450 (derivative) · Grant/award (A): 161,810 (derivative) · Grant/award (A): 22,740 (derivative) | EDGAR |
| 2024-12-17 | 4 | PALVELLA THERAPEUTICS, INC. (PVLA) jointly with BVF PARTNERS L P/IL, BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL, LAMPERT MARK N | Other (J): 234,323 · Other (J): 174,958 · Other (J): 29,648 | EDGAR |
| 2024-12-04 | 4 | Olema Pharmaceuticals, Inc. (OLMA) jointly with BVF PARTNERS L P/IL, BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL, LAMPERT MARK N | Disposition to issuer (D): 1,797,527 · Disposition to issuer (D): 1,418,736 · Disposition to issuer (D): 153,441 · Grant/award (A): 1,797,527 (derivative) · Grant/award (A): 1,418,736 (derivative) · Grant/award (A): 153,441 (derivative) · +3 more | EDGAR |
| 2024-11-13 | 4 | 4D Molecular Therapeutics, Inc. (FDMT) jointly with BVF PARTNERS L P/IL, BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL, LAMPERT MARK N | Other (J): 3,062,000 · Other (J): 2,378,000 · Other (J): 240,000 · Other (J): 3,062,000 (derivative) · Other (J): 2,378,000 (derivative) · Other (J): 240,000 (derivative) | EDGAR |
| 2024-10-31 | 4 | Eledon Pharmaceuticals, Inc. (ELDN) jointly with BVF PARTNERS L P/IL, BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL, LAMPERT MARK N | Purchase (P): 2,213,816 (derivative) @ $3.65 · Purchase (P): 2,100,244 (derivative) @ $3.65 · Purchase (P): 440,489 (derivative) @ $3.65 | EDGAR |
| 2024-10-31 | 4 | Third Harmonic Bio, Inc. (THRD) jointly with BVF PARTNERS L P/IL, BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL, LAMPERT MARK N | Sale (S): 538,420 @ $14.30 · Sale (S): 396,963 @ $14.30 · Sale (S): 64,617 @ $14.30 | EDGAR |
| 2024-10-08 | 4 | MoonLake Immunotherapeutics (MLTX) jointly with BVF PARTNERS L P/IL, BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL, LAMPERT MARK N | Sale (S): 1,030,589 @ $50.00 · Sale (S): 836,862 @ $50.00 · Sale (S): 132,549 @ $50.00 | EDGAR |
| 2024-08-22 | 4 | Kymera Therapeutics, Inc. (KYMR) jointly with BVF PARTNERS L P/IL, BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL, LAMPERT MARK N | Purchase (P): 201,546 (derivative) @ $40.75 · Purchase (P): 156,742 (derivative) @ $40.75 | EDGAR |
| 2024-06-28 | 4 | Kymera Therapeutics, Inc. (KYMR) jointly with BVF PARTNERS L P/IL, BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL, LAMPERT MARK N | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Olema Pharmaceuticals, Inc. (OLMA) jointly with BVF PARTNERS L P/IL, BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL, LAMPERT MARK N | Grant/award (A): 23,000 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | MoonLake Immunotherapeutics (MLTX) jointly with BVF PARTNERS L P/IL, BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL, LAMPERT MARK N | Grant/award (A): 7,688 (derivative) @ $0 | EDGAR |
| 2024-05-13 | 4 | Eledon Pharmaceuticals, Inc. (ELDN) jointly with BVF PARTNERS L P/IL, BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL, LAMPERT MARK N | Purchase (P): 1,031,385 · Purchase (P): 821,121 · Purchase (P): 75,431 · Purchase (P): 3,173,135 (derivative) · Purchase (P): 2,526,238 (derivative) · Purchase (P): 232,068 (derivative) | EDGAR |
| 2024-01-29 | 4 | Rain Oncology Inc. (RAIN) jointly with BVF PARTNERS L P/IL, BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL, LAMPERT MARK N | Code (U): 1,734,960 · Code (U): 2,870,985 · Code (U): 1,367,838 · Code (U): 2,076,085 · Code (U): 185,388 · Code (U): 341,547 · +2 more | EDGAR |
| 2024-01-09 | 4 | Kymera Therapeutics, Inc. (KYMR) jointly with BVF PARTNERS L P/IL, BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL, LAMPERT MARK N | Purchase (P): 550,425 (derivative) @ $25.25 · Purchase (P): 375,856 (derivative) @ $25.25 · Purchase (P): 52,733 (derivative) @ $25.25 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-09 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1660683 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →